IRVINE, Calif., Feb. 28, 2008 (PRIME NEWSWIRE) -- "For small cap companies, awards earned in the universe of all companies certainly attest to the potential of said equity," stated SmallCap Sentinel analyst D.R. Clark. "Selection as the recipient of the Frost & Sullivan 2008 North America Technology Innovation Award in the field of interventional cardiology should send a boldly written memo to the investing public that there's something to follow at MIV Therapeutics, Inc. (OTCBB:MIVT)."
Financial content focusing on MIV Therapeutics Inc. and developments in cardiovascular stents and drug delivery has been made available to the investing public. These items will feature detailed information regarding MIVT, its field and is of interest to Johnson & Johnson (NYSE:JNJ) Medtronic Inc. (NYSE:MDT), and Boston Scientific (NYSE:BSX).
To view the corporate presentation visit: http://mivtherapeutics.com/inSitePresent/
To view the Frost and Sullivan Award in detail visit: http://admin.blendermedia.com/staging/mivtherapeutics.com/_resources/frost_award_2008.pdf
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $24,000 by MIV Therapeutics for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.